Theravance Biopharma, Inc. (TBPH)

Market Cap	471.58M
Revenue (ttm)	63.19M
Net Income (ttm)	-49.40M
Shares Out	49.17M
EPS (ttm)	-1.01
PE Ratio	n/a
Forward PE	36.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	249,828
Open	9.65
Previous Close	9.73
Day's Range	9.56 - 9.83
52-Week Range	7.44 - 11.71
Beta	0.22
Analysts	Buy
Price Target	13.75 (+43.38%)
Earnings Date	Nov 12, 2024

About TBPH

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collabora...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 99
• Stock Exchange: NASDAQ
• Ticker Symbol: TBPH
• Website: https://www.theravance.com

Analyst Forecast

According to 4 analysts, the average rating for TBPH stock is "Buy." The 12-month stock price forecast is $13.75, which is an increase of 43.38% from the latest price.

Price Target

$13.75

(43.38% upside)

Analyst Consensus: Buy